Using the Tools we Have: Low-efficacy Vaccines and HIV.
作者信息
Zurakowski Ryan
机构信息
Department of Biomedical Engineering, University of Delaware, Newark, DE 19716, USA.
出版信息
EBioMedicine. 2015 Dec 12;2(12):1867-8. doi: 10.1016/j.ebiom.2015.12.007. eCollection 2015 Dec.
Abstract
摘要
相似文献
1
Using the Tools we Have: Low-efficacy Vaccines and HIV.利用我们现有的工具：低效疫苗与艾滋病毒
EBioMedicine. 2015 Dec 12;2(12):1867-8. doi: 10.1016/j.ebiom.2015.12.007. eCollection 2015 Dec.
2
HIV vaccine efficacy trials: towards the future of HIV prevention.HIV疫苗效力试验：迈向HIV预防的未来
Infect Dis Clin North Am. 2007 Mar;21(1):201-17, x. doi: 10.1016/j.idc.2007.01.006.
3
What hope is there for an HIV vaccine?艾滋病疫苗的前景如何？
S Afr Med J. 2004 Oct;94(10):831.
4
Is the current use of 'positivity' thresholds meaningful for evaluating HIV-vaccine immunogenicity endpoints?目前使用的“阳性率”阈值对于评估HIV疫苗免疫原性终点指标是否有意义？
AIDS. 2013 May 15;27(8):1362-5. doi: 10.1097/QAD.0b013e328360d52e.
5
Phase 1 clinical trials of the National Institutes of Health Vaccine Research Center HIV/AIDS candidate vaccines.美国国立卫生研究院疫苗研究中心针对人类免疫缺陷病毒/艾滋病候选疫苗开展的1期临床试验。
J Infect Dis. 2006 Dec 15;194(12):1625-7. doi: 10.1086/509263. Epub 2006 Nov 8.
6
The HVTN 503/Phambili study: efficacy is always the issue.HVTN 503/Phambili研究：疗效始终是关键问题。
Lancet Infect Dis. 2011 Jul;11(7):490-1. doi: 10.1016/S1473-3099(11)70103-7. Epub 2011 May 11.
7
Immune responses to HIV vaccines and potential impact on control of acute HIV-1 infection.HIV 疫苗的免疫反应及其对急性 HIV-1 感染控制的潜在影响。
J Infect Dis. 2010 Oct 15;202 Suppl 2(Suppl 2):S323-6. doi: 10.1086/655658.
8
The RV144 Thai HIV vaccine trial.RV144泰国艾滋病疫苗试验。
Hum Vaccin. 2010 Feb;6(2):159. Epub 2010 Feb 18.
9
Challenges in the development of an HIV-1 vaccine.人类免疫缺陷病毒1型疫苗研发中的挑战。
Nature. 2008 Oct 2;455(7213):613-9. doi: 10.1038/nature07352.
10
The 2017 Keystone Symposium on HIV Vaccines.2017年艾滋病疫苗关键研讨会
Hum Vaccin Immunother. 2017 Oct 3;13(10):2348-2351. doi: 10.1080/21645515.2017.1353852.
引用本文的文献
1
Significant Unresolved Questions and Opportunities for Bioengineering in Understanding and Treating COVID-19 Disease Progression.生物工程在理解和治疗COVID-19疾病进展方面存在的重大未解决问题与机遇
Cell Mol Bioeng. 2020 Jul 27;13(4):259-284. doi: 10.1007/s12195-020-00637-w. eCollection 2020 Aug.
本文引用的文献
1
Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models.基于数学模型的分析：分支特异性 HIV 疫苗是否有必要？
EBioMedicine. 2015 Nov 5;2(12):2062-9. doi: 10.1016/j.ebiom.2015.11.009. eCollection 2015 Dec.
2
PUBLIC HEALTH. Toward an HIV vaccine: A scientific journey.公共卫生。迈向HIV疫苗：一段科学之旅。
Science. 2015 Jul 24;349(6246):386-7. doi: 10.1126/science.aac6300. Epub 2015 Jul 23.
3
New approaches to HIV vaccine development.艾滋病病毒疫苗研发的新方法。
Curr Opin Immunol. 2015 Aug;35:39-47. doi: 10.1016/j.coi.2015.05.007. Epub 2015 Jun 8.
4
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.在泰国使用ALVAC和AIDSVAX疫苗预防HIV-1感染。
N Engl J Med. 2009 Dec 3;361(23):2209-20. doi: 10.1056/NEJMoa0908492. Epub 2009 Oct 20.
5
Mathematical models of vaccination.疫苗接种的数学模型
Br Med Bull. 2002;62:187-99. doi: 10.1093/bmb/62.1.187.
6
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.HIV-1感染中血浆病毒粒子和CD4淋巴细胞的快速周转。
Nature. 1995 Jan 12;373(6510):123-6. doi: 10.1038/373123a0.
Zotero 插件